Brevibacillus laterosporus

Other Names

B. laterosporusBacillus laterosporus

Synopsis

Brevibacillus laterosporus: A Comprehensive Reference

1. Identity and Classification

1.1 Taxonomic and Nomenclatural History

Brevibacillus laterosporus is a gram-positive, spore-forming bacterium widely recognized as an insect pathogen and a beneficial agricultural bioagent, in the family Brevibacillaceae. Osamu Shida and co-workers created the new genus Brevibacillus in 1996 with a correction published in 1997. Originally described as Bacillus laterosporus, the genus was distinguished from the genus Bacillus by Shida et al. based on 16S rDNA sequences. The species was first identified in 1912 and previously belonged to the Bacillus brevis cluster.

Within the broader bacterial phylogeny, Brevibacillus laterosporus is a species of firmicute in the family Paenibacillaceae — though more recent taxonomic authorities, including Wikipedia and primary literature, place it in Brevibacillaceae. Across the primary literature its full binomial remains Brevibacillus laterosporus (Laubach 1916) Shida et al. 1996. In older commercial and patent literature it appears under its former name Bacillus laterosporus, a synonym still in wide use in the dietary supplement industry.

1.2 Morphological Identity and Natural Sources

The bacterium is characterized by the production of a unique canoe-shaped lamellar body attached to one side of the spore, and is a natural inhabitant of water, soil, and insects. More precisely, it is characterized by the production of a typical canoe-shaped parasporal body (CSPB) which remains firmly attached to one side of the spore after lysis of the sporangium.

Brevibacillus laterosporus is aerobic, gram-positive, and an endospore-forming bacterium which can also be a facultative anaerobe. This species commonly inhabits soil, freshwater, seawater, insect bodies, leaf surfaces, and fermented foods. Brevibacillus laterosporus is a globally ubiquitous, spore-forming bacterium, strains of which have shown toxic activity against invertebrates and microbes, and several have been patented due to their commercial potential.

1.3 Key Strains and Commercial Preparations

Multiple strains of B. laterosporus have been characterized. The most commercially prominent in the dietary supplement context is the B.O.D. strain (also designated with ATCC Accession Number ATCC 55122). The B.O.D. strain was originally isolated from a soil sample from Iceland and was selected for further research based on its ability to inhibit pathogenic bacteria in soil and lab test media. The organism has the identifying characteristics of the organism having ATCC Accession Number ATCC 55122.

Other notable strains investigated in the scientific literature include BL1 (studied for anti-obesity effects in animal models), TSA31-5 (characterized for dual antibiotic production), DSM25 (studied as a probiotic bacterial strain), BF202 (isolated from the hypersaline Mariout Lake), and XJ-24-3 (isolated from Xinjiang, China). Research strains from silage, red clay soil, marine environments, and poultry settings have also been extensively characterized. This species appears to have evolved multifunctional roles in nature, leveraging its probiotic, antimicrobial, biofertilizer, and biopesticidal potential.

In the dietary supplement market, B. laterosporus (B.O.D. strain) is principally sold as oral capsule formulations. Because it is a spore-forming organism, it does not require refrigeration and its spores are stable under ambient conditions, a property that distinguishes it from vegetative probiotic strains.

2. Traditional and Historical Use

2.1 Botanical and Microbial Context

Unlike botanical herbs with documented indigenous use over centuries, Brevibacillus laterosporus has no established place in any classical ethnobotanical or ethnomedicinal tradition. It was first described by Laubach (1916) as an aerobic, gram-positive, endospore-forming bacterium. Its entry into the human health supplement space is modern and commercial rather than rooted in documented traditional medicine systems.

It has been found as a secondary invader during European foulbrood, which is a serious infectious disease of honey bees, indicating its ecological presence in settings familiar to pre-modern agriculture, but no formal traditional medicinal use in that context is documented in the peer-reviewed record.

2.2 Commercial and Patent History

The narrative that drives the current supplement market for B. laterosporus derives principally from commercial and patent history. The B.O.D. strain was originally isolated from a soil sample from Iceland and was selected for further research based on its ability to inhibit pathogenic bacteria in soil and lab test media. The strain designated BOD was characterized as non-pathogenic, and methods employing it were described as relying upon "natural" mechanisms of controlling disease — specifically fungal disease in animal production contexts.

In the dietary supplement industry, the bacterium gained recognition primarily through a U.S. patent filed in the mid-1990s covering its use as an antifungal agent in animals, with the B.O.D. strain deposited under ATCC 55122. Claims in commercial literature that the organism was "discovered" in Icelandic soil by an agriculturalist and subsequently developed as a probiotic supplement reflect this patent history rather than a documented tradition of human therapeutic use. No peer-reviewed or government source verifies a pre-modern ethnomedicinal tradition of use in any culture.

3. Key Constituents and Active Compounds

Brevibacillus laterosporus is a prolific producer of secondary metabolites, the characterization of which has been a central focus of modern microbiological research. AMPs produced by members of the genus Brevibacillus, particularly Brevibacillus laterosporus, include defensin-like antimicrobial peptides, antibiotics like laterosporamine, acyl dipeptides like tupuselei amides, antifungal polyketides like basiliskamides, lipopeptide antibiotic like tauramamide, cyclodecapeptides like laterocidin and its analogues which inhibit growth of both Gram-positive and Gram-negative bacteria. Additionally, novel thrombin inhibitors like bacithrocins A, B and C and anticancer antibiotic like spergualin are also reported from strains of B. laterosporus.

3.1 Brevilaterins (Brevilaterin A–E and Brevibacillins)

Brevilaterins (including Brevilaterin A–E and Brevibacillins) are antimicrobial lipopeptides isolated from B. laterosporus that are natural antibacterial agents and cationic bacitracins against drug-resistant bacteria. This lipopeptide maintains good stability at 121°C and pH 2–12. The minimum inhibitory concentration of Brevilaterins against Bacillus, Listeria, Streptococcus, Lactobacillus, and other bacteria ranged from 0.5 to 2 µg/mL.

Mechanism of action: The bactericidal activity of Brevilaterins secreted by B. laterosporus is attributed to their ability to bind to lipopolysaccharide/lipid II molecules on the cell membrane, thereby altering permeability. Brevilaterins also inhibit bacterial reproduction by affecting relevant gene pathways in the cell membranes of pathogenic bacteria. These pathways include ATP synthesis, peptidoglycan biosynthesis, membrane transport, and cellular metabolism.

3.2 Brevibacillin

The recently characterized B. laterosporus OSY-I1 produces brevibacillin, a 1583 Da antimicrobial lipopeptide with a linear structure containing 13 amino acids and a C6 fatty acid at the N-terminus. Brevibacillin shows strong antimicrobial activity against some pathogenic and food-spoilage Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus, Listeria monocytogenes, and Bacillus cereus.

The mechanism of action of this molecule is most likely based on its amphiphilic nature and the ability of the cationic amino acids to interact with the negatively charged phospholipids of the cell membrane, causing the disruption and depolarization of the membrane.

3.3 Brevicidine

A novel Brevibacillus laterosporus strain simultaneously produces brevicidine and brevibacillin peptides that selectively and potently act on Gram-negative and Gram-positive bacteria. Brevicidine displayed notable antibacterial activity against Gram-negative bacteria, with a minimum inhibitory concentration (MIC) range of 1–8 μg/mL. Brevibacillin exhibited robust antimicrobial effectiveness against both Gram-positive bacterial strains (MIC range of 2–4 μg/mL) and Gram-negative bacteria (MIC range of 4–64 μg/mL). Brevicidine exhibited no hemolysis or cytotoxicity up to 512 μg/mL, comparable to the negative control, suggesting its promising therapeutic potential in treating infectious diseases.

3.4 Laterosporulin and Laterosporulin 10

Laterosporulin is active against both Gram-positive and Gram-negative bacteria and was found to be resistant to a range of proteolytic enzymes. Structural studies revealed that the peptide consists of twisted β-sheet and includes three disulfide bonds. Laterosporulin is relatively rich in cysteine and polar amino acids, which is atypical for bacteriocins in general, whereas its structure showed similarities with mammalian defensins.

Laterosporulin 10, produced by the strain Brevibacillus sp. SKDU10, was characterized and, while considered similar, shows only 57.6% identity with laterosporulin. This novel bacteriocin has a different antimicrobial spectrum to laterosporulin as activity is limited to Gram-positive bacteria. However, laterosporulin 10 has also proven to be a promising new anti-cancer molecule that exhibits a cytotoxic effect on cancer cells.

3.5 Basiliskamides, Bogorols, and Loloatins

The marine bacterial isolate Brevibacillus laterosporus PNG-276 showed broad-spectrum antibiotic activity, producing polyketides the basiliskamides A and B and nonribosomal peptides: loloatins A–D and bogorols A–E, active against the human pathogens MRSA, VRE, Mycobacterium tuberculosis, Candida albicans, and Escherichia coli.

3.6 Chitinolytic Enzymes

Strains of B. laterosporus produce extracellular chitinase or chitinolytic enzymes that contribute to its antifungal role. These enzymes degrade chitin, a structural component of fungal cell walls, providing a mechanistic basis for the organism's antifungal activity.

3.7 Defensin-Like Bacteriocin Laterosporulin25 (LS25)

A novel defensin-like bacteriocin, laterosporulin25 (LS25), was identified upon genome mining of Brevibacillus laterosporus DSM25, a probiotic bacterial strain. LS25 is characterized as a defensin-like bacteriocin, having 51 amino acids and a molecular weight of 5862.7 Da. The modeled tertiary structure of LS25 has been docked with TLR3 and TLR4-MD2 complex to confirm the facilitation of induced immune response, further validated using molecular dynamics simulations and in silico immune stimulations. Detailed immunoinformatics analysis suggested LS25 as a potential candidate for use as an adjuvant or carrier protein for subunit vaccine development; however, further in vitro and in vivo experiments are essential to validate its potential.

3.8 Genomic Diversity of Bioactive Compounds

Research indicates that B. laterosporus can produce a diverse range of metabolites with bacteriostatic properties, such as brevilaterins A–E, brevibacillin, and others. Bioinformatic mining has predicted biosynthetic potential for antimicrobial compounds including bogorol A, laterosporulin, and linear azol(in)e-containing peptides. Importantly, while all of the genomes examined shared some putative toxicity or virulence related proteins, many specific genes were only present in a subset of strains, and the toxin complement varied from isolate to isolate. This inter-strain variability is critically important for evaluating the properties of any specific commercial preparation, since different strains of the same species may have substantially different metabolite profiles and, consequently, different biological properties.

4. Mechanisms of Action

4.1 Antimicrobial Activity

Different B. laterosporus strains show broad-spectrum antimicrobial activity including activity against phytopathogenic bacteria and fungi. A wide variety of molecules, including proteins and antibiotics, have been associated with the observed pathogenicity and mode of action.

The primary antimicrobial mechanism involves cell membrane disruption. The bactericidal activity of Brevilaterins secreted by B. laterosporus is attributed to their ability to bind to lipopolysaccharide/lipid II molecules on the cell membrane, thereby altering permeability. Scanning electron microscopy analysis and fluorescence assays uncovered distinctive morphological alterations in bacterial cell membranes induced by brevicidine and brevibacillin, implying distinct mechanisms of antibacterial activity exhibited by the different peptides.

4.2 Antifungal Mechanism

Enzymatic destruction of fungi has been reported in the literature. Strains of B. laterosporus produce extracellular chitinase or chitinolytic enzymes that contribute to its antifungal role. Chitinases hydrolyze the β-1,4-glycosidic bonds of chitin, degrading the structural scaffold of fungal cell walls and resulting in organism death or growth inhibition.

4.3 Gut Microbiota Modulation

B. laterosporus has been used to improve animal production by regulating the structure of the intestinal microbiota and inhibiting the growth of pathogenic bacteria through the secretion of various antimicrobial peptides. In animal studies, this modulation has been associated with altered ratios of major microbial phyla and increased production of short-chain fatty acids (SCFAs) by resident microbiota.

4.4 Crop and Plant Growth Promotion

B. laterosporus enhances crop cultivation by secreting hydrolases to improve nutrient absorption capabilities, synthesizing hormones to promote crop growth, and producing proteins to inhibit the reproduction of harmful organisms. These mechanisms are relevant to the organism's use as a biofertilizer and biocontrol agent but have not been directly studied in human health contexts.

5. Scientific Evidence by Area of Use

5.1 Antimicrobial Activity: In Vitro Evidence

Evidence strength: Substantial in vitro; no human clinical trials.

Before being considered as a biological control agent against plant pathogens, the antifungal and antibacterial properties of certain B. laterosporus strains have found medical interest, associated with the production of antibiotics with therapeutic effects.

Multiple laboratory studies have documented the antimicrobial spectrum of B. laterosporus metabolites. Brevibacillin shows strong antimicrobial activity against some pathogenic and food-spoilage Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus, Listeria monocytogenes, and Bacillus cereus. The marine isolate B. laterosporus PNG-276 showed broad-spectrum antibiotic activity against MRSA, VRE, Mycobacterium tuberculosis, Candida albicans, and Escherichia coli.

A 2024 study isolated the novel strain XJ-24-3 from Xinjiang, China, and found bioinformatic mining predicted biosynthetic potential for antimicrobial compounds — bogorol A, laterosporulin, and linear azol(in)e-containing peptides — positioning XJ-24-3 as a promising source of novel broad-spectrum antimicrobial agents. The study elucidated the genomic characteristics of the isolate and uncovered the genetic basis for its antibacterial properties, providing a theoretical foundation for the development of novel antibacterial proteins.

All antimicrobial evidence for B. laterosporus in a human health context remains at the in vitro (cell culture or microbiological assay) stage. There are no controlled human clinical trials evaluating the organism or its metabolites as antibacterial or antifungal therapeutic agents in humans.

5.2 Antifungal Activity and Candida: In Vitro and Patent Evidence

Evidence strength: In vitro and patent-derived; no human clinical trials.

The claim that B. laterosporus can combat Candida species is among the most widely cited in the supplement industry. Mechanistically, strains of B. laterosporus produce extracellular chitinase or chitinolytic enzymes that contribute to its antifungal role. In vitro studies have demonstrated activity against Candida albicans and Aspergillus species. The B.O.D. strain was described as non-pathogenic in patent documentation.

The 1994 patent (US5455028) covering the method of inhibiting fungi by Bacillus laterosporus strain BOD provides proof-of-concept data from in vitro and laboratory animal contexts, but it is not a clinical study. No peer-reviewed randomized controlled trials in humans evaluating B. laterosporus as an anti-candida probiotic have been identified in the published literature.

5.3 Gut Health and Probiotic Applications: Animal Evidence

Evidence strength: Predominantly animal/poultry models; no human clinical trials identified.

The most substantial scientific body of work on B. laterosporus as a probiotic concerns animal production. B. laterosporus has been used to improve animal production by regulating the structure of the intestinal microbiota and inhibiting the growth of pathogenic bacteria through the secretion of various antimicrobial peptides.

A 2025 study published in Frontiers in Microbiology investigated the effects of dietary supplementation with B. laterosporus in broilers. A total of 320 one-day-old male broilers were randomly assigned to four dietary groups: control (CON), low-dose (LBL, 100 mg/kg), medium-dose (MBL, 300 mg/kg), and high-dose (HBL, 500 mg/kg) B. laterosporus supplementation, with 8 replicates per group and 10 chicks per replicate. Dietary supplementation with B. laterosporus significantly decreased the feed-to-gain ratio in the LBL, MBL, and HBL groups. Both MBL and HBL groups showed higher semi-eviscerated percentages than the control. The MBL group had a significantly increased eviscerated percentage. The LBL group had a significantly increased breast muscle percentage. These outcomes are relevant to poultry production but have not been translated into human trials.

A 2026 study published in Scientific Reports evaluated B. laterosporus strain PBC01 as a feed additive in chickens, examining effects on growth performance, antioxidant capacity, immunological capability, intestinal tight junction proteins, and intestinal flora. Previous laboratory studies have shown it has a wide range of probiotic properties and good safety. Again, this is poultry-specific research.

5.4 Anti-Obesity and Metabolic Effects: Animal Evidence

Evidence strength: Single animal (murine) study; preliminary; not replicated in humans.

A 2022 study published in Frontiers in Nutrition (PMC9729748) investigated the strain B. laterosporus BL1, which was isolated from earthworm intestine. The study aimed to investigate the effects of B. laterosporus BL1 on preventing obesity in high-fat diet (HFD)-fed mice. C57BL/6 male mice were randomly assigned to four groups (n = 10) and fed a control diet, HFD, HFD plus B. laterosporus BL1, and HFD plus supernatant of B. laterosporus BL1, respectively for 8 weeks.

The results showed that prophylactic B. laterosporus BL1 treatment reduced body weight gain by 41.26% in comparison to the HFD group, and this difference was accompanied by a reduction in body fat mass and the weight of inguinal white adipose tissues and epididymal white adipose tissue (−33.39%, −39.07%, and −43.75%, respectively).

Moreover, the B. laterosporus BL1-mediated improvements in lipid profile, insulin resistance, and chronic inflammation were associated with the regulation of gene expression related to lipid metabolism and enhancement of brown adipose tissue thermogenesis. The intervention significantly improved HFD-induced gut flora dysbiosis, as evidenced by a reverse in the relative abundance of Bacillota and Bacteroidota, as well as an increase in the relative abundance of bacteria that produce short-chain fatty acids (SCFAs), which in turn increased SCFAs levels.

The authors concluded that B. laterosporus BL1 may be a promising probiotic for prevention of obesity associated with the regulation of gut microbiota. This remains a single preclinical mouse study requiring human replication before any conclusions about efficacy in humans can be drawn.

5.5 Anticancer Properties: In Vitro Evidence

Evidence strength: In vitro (cell lines) only; highly preliminary; no animal or human trials.

Several B. laterosporus-derived compounds have shown cytotoxicity against cancer cell lines in in vitro assays.

Laterosporulin 10 (LS10) has been the most studied. LS10 displayed cytotoxicity against cancer cells like MCF-7, HEK293T, HT1080, HeLa, and H1299 at below 10 μM concentration, but not against prostate epithelium cells RWPE-1. Flow cytometry analysis of treated cancer cell lines revealed that LS10 induces apoptosis even at 2.5 μM concentration. The results demonstrated that LS10 did not show any cytotoxicity against normal cells up to 15 μM, while significant cytotoxicity was observed against cancer cell lines at this concentration.

Brevilaterin B has also been studied for anticancer properties. Brevilaterin B exhibited broad-spectrum anticancer activity in a dose-dependent manner. It selectively inhibited the proliferation of epidermal cancer cell A431 but had no effect on its control normal cells in a dose of 2.0 µg/mL. Typical morphological characteristics of apoptosis and an apoptotic ratio of 71.0% in A431 were observed after treatment by 2.0–3.0 µg/mL of Brevilaterin B. The ROS levels increased by 21.3% and mitochondrial membrane potential reduced by 48.8%, indicating Brevilaterin B's anticancer action was mainly focused on the mitochondrion of cancer cells.

Recent studies have shed light on the potential therapeutic properties of these AMPs, including Bogorol B-JX, which has been shown to inhibit the proliferation of human histiocytic lymphoma cell lines and ConA-activated spleen cells, and Spergualin, which has demonstrated promising antitumor activity against transplantable leukemias in mice. These findings highlight the potential of Brevibacillus laterosporus and its AMPs as a novel source of anticancer agents for future development. These are in vitro and murine findings and have not been evaluated in human clinical trials.

5.6 Immunomodulation: In Silico and Preliminary Evidence

Evidence strength: In silico modeling only; no human or clinical data.

The modeled tertiary structure of the bacteriocin LS25 has been docked with TLR3 and TLR4-MD2 complex to confirm the facilitation of induced immune response, further validated using molecular dynamics simulations and in silico immune simulations. Detailed immunoinformatics analysis suggested LS25 as a potential candidate for adjuvant or carrier protein for subunit vaccine development; however, further in vitro and in vivo experiments are essential to validate its potential. This is entirely computational work without experimental validation in biological systems.

5.7 Biopesticidal and Insecticidal Activity

Brevibacillus laterosporus is defined as an insecticidal bacterium that is active against various insect species, including Coleoptera, Lepidoptera, and Diptera, and is being developed as an active agent in biopesticides, particularly from local strains in New Zealand. Its biopesticidal potential has been reported against insects in different orders including Coleoptera, Lepidoptera, Diptera, and against nematodes and mollusks. This area of research is well established in the agricultural science literature and represents the species' best-characterized activity. It is not directly relevant to human supplementation, but does inform the organism's overall biological profile.

6. Body Systems and Health Areas of Association

Gastrointestinal / Gut Microbiome: Animal model data suggest potential to modulate intestinal microbiota composition, increase SCFA-producing bacteria, and inhibit pathogenic bacteria. No human clinical data.
Metabolic / Adipose: One murine study showed reduction in high-fat-diet-induced weight gain and improvements in lipid profile and insulin resistance. No human data.
Antimicrobial / Infectious Disease: Extensive in vitro data across multiple metabolite classes (brevilaterins, brevibacillin, brevicidine, basiliskamides, bogorols) demonstrate activity against a range of Gram-positive and Gram-negative bacterial pathogens. Particularly noted activity against MRSA, Listeria, Mycobacterium tuberculosis, and Candida albicans. All evidence is preclinical.
Oncology (Experimental): In vitro evidence for cytotoxicity of LS10, Brevilaterin B, and other AMPs against multiple cancer cell lines. All evidence is in vitro only.
Immunological: In silico modeling of LS25 interaction with Toll-like receptor complexes. No experimental or clinical data.
Agricultural / Veterinary: The most evidence-rich domain. Well-documented effects on gut microbiota composition and growth performance in poultry, which are not directly translatable to humans.

7. Dosage Forms and Reported Dosages

Dosage information in the peer-reviewed literature pertains almost exclusively to animal production studies, not human supplementation trials.

Poultry supplementation (2025 study, Frontiers in Microbiology): Low-dose (LBL): 100 mg/kg feed; medium-dose (MBL): 300 mg/kg feed; high-dose (HBL): 500 mg/kg feed.
Murine anti-obesity study (2022, Frontiers in Nutrition): Administered to C57BL/6 male mice fed a high-fat diet plus B. laterosporus BL1 or its supernatant for 8 weeks. Precise dose in colony-forming units or milligrams per kilogram is not specified in the abstract-level data available.
Anticancer in vitro studies: Compound concentrations tested in cell culture experiments are reported in micromolar quantities (e.g., LS10 at below 10 μM; Brevilaterin B at 2.0 µg/mL) and are not translatable to human oral dosing recommendations.
Supplement products (commercial): Commercial supplement products based on the B.O.D. strain exist, but no peer-reviewed source documents a validated human oral dosage for any health endpoint. The absence of human clinical trials means that no evidence-based dosing range for human use can be stated.

8. Safety Considerations

8.1 Rarity of Human Infection

Brevibacillus laterosporus is an aerobic gram-positive bacillus that is rarely associated with human infection. A review of multiple online databases revealed no other cases of bacteremia in an adult involving this organism — as of the 2020 case report. This "canoe-shaped" microbe has been characterized as a pathogen in invertebrates, and information regarding human infection is scarce. The 2020 report was described as the first reported case of B. laterosporus bacteremia in an adult human subject.

A subsequent case was documented in the European Journal of Case Reports in Internal Medicine, involving osteomyelitis and hardware infection. Brevibacillus laterosporus is not only a potential biocontrol agent against plant pathogens but also a rare cause of human infection. Its pathogenicity in humans, especially in immunocompetent individuals, is still not fully understood. Skin infections caused by B. laterosporus are typically opportunistic, entering the skin through cuts, wounds, or other breaches in the skin's protective barrier.

8.2 Opportunistic Nature of Reported Infections

Skin infections caused by Brevibacillus laterosporus are generally considered opportunistic and more likely to occur in individuals with compromised immune systems or pre-existing skin conditions. Brevibacillus laterosporus infections in immunocompetent patients are exceedingly rare, and information about optimal treatment strategies is limited. The two documented cases of systemic human infection both involved hosts with significant underlying immune vulnerability.

Human infection by B. laterosporus is rare, and numerous obstacles exist in the identification and treatment of such infections. Given the lack of reported breakpoints or literature supporting treatment modalities, antibiotic selection against this organism is challenging. Hosts of B. laterosporus may be immunocompromised, and unique microbiologic characteristics of this organism complicate its identification.

8.3 Strain-Level Variation in Toxin Genes

While all of the genomes examined shared some putative toxicity or virulence related proteins, many specific genes were only present in a subset of strains, and the toxin complement varied from isolate to isolate. Variation in occurrence of toxin-encoding genes indicates the potential to find strains with new combinations of activities. This inter-strain variability is a key safety consideration: the risk profile of any specific commercial strain cannot be extrapolated from data on other strains without independent characterization.

8.4 Cytotoxicity of Some Metabolites

Brevibacillin demonstrated elevated cytotoxicity in in vitro assays. Nonetheless, owing to its noteworthy antimicrobial activity against pathogenic bacteria, brevibacillin could still be explored as a promising antimicrobial agent. This indicates that not all metabolites produced by B. laterosporus strains are without cytotoxic potential, a distinction relevant when considering the organism as a dietary supplement.

8.5 Absence of Formal Safety Evaluation for Human Supplementation

No government regulatory body — including the U.S. FDA, EFSA, or EFSA's Qualified Presumption of Safety (QPS) list — has formally evaluated Brevibacillus laterosporus for use as a human probiotic dietary supplement in peer-reviewed documentation identified in this search. B. laterosporus exhibits substantial potential as a probiotic in crop and animal production. However, applications of B. laterosporus in animal production could be improved, necessitating further research to elucidate the underlying probiotic mechanisms. The overall safety profile in healthy human subjects has not been established through clinical investigation.

8.6 Potential for Insecticidal Compounds to Persist in the Gut

The oral administration of the entomopathogenic bacterium Brevibacillus laterosporus to caged poultry allows the homogeneous incorporation of its active ingredients with fly breeding media. Feces from treated broilers or hens show toxicity against exposed fly adults and larvae. This finding suggests that biologically active insecticidal compounds can survive gastrointestinal transit after oral administration. The implications for human consumers of probiotic preparations containing the organism have not been studied.

9. Summary of Evidence Quality

The evidence base for Brevibacillus laterosporus as a human dietary supplement is, as of mid-2026, entirely preclinical. Its properties are well-characterized in vitro and in agricultural animal models. The organism produces a remarkable diversity of bioactive secondary metabolites with antimicrobial, antifungal, and putative anticancer properties that are compelling from a basic-science standpoint. However, B. laterosporus exhibits substantial potential as a probiotic in crop and animal production; however, applications in animal production could be improved, necessitating further research to elucidate the underlying probiotic mechanisms. No controlled human clinical trials for any health outcome have been identified. The strain-level variability in toxin gene complement, the documented (though rare) capacity for opportunistic human infection, and the lack of formal regulatory safety evaluation for human probiotic use represent important knowledge gaps that preclude confident evidence-based recommendations. Few studies have been conducted on its use as a feed additive in animals, and the human supplementation evidence base is even more limited.

References

Health Conditions

Health conditions that Brevibacillus laterosporus may help support.

No conditions available.

Body Systems

Body systems that Brevibacillus laterosporus may help support.

No body systems available.